-
Posted by
Two Blokes Apr 22 -
Filed in
Stock
-
4 views
Shares in Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013) rose 10% in early trading on Tuesday after the biopharma company announced it had completed patient enrolment for a key phase II trial of its cancer drug savolitinib in China. The study is testing the treatment in people with gastric or gastroesophageal junction cancer whose tumours show MET gene amplification - a relatively rare but aggressive subtype.
